Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of JNJ-40929837 in Mild Atopic Asthma Using Bronchial Allergen Challenge
2010-022437-28Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-40929837 in asthma (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Maximal percent fall in FEV1 during late asthmatic response. Started Sep 2010; status: completed.
02
Drugs
JNJ-40929837
03
Conditions
asthma
Beyond the preview
Go deeper on 2010-022437-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022437-28.